Literature DB >> 7678603

Peptidase modulation of vasoactive intestinal peptide pulmonary relaxation in tracheal superfused guinea pig lungs.

C M Lilly1, M A Martins, J M Drazen.   

Abstract

The effects of enzyme inhibitors on vasoactive intestinal peptide (VIP)-induced decreases in airway opening pressure (PaO) and VIP-like immunoreactivity (VIP-LI) recovery were studied in isolated tracheal superfused guinea pig lungs. In the absence of inhibitors, VIP 0.38 (95% CI 0.33-0.54) nmol/kg animal, resulted in a 50% decrease in PaO and 33% of a 1 nmol/kg VIP dose was recovered as intact VIP. In the presence of two combinations of enzyme inhibitors, SCH 32615 (S, 10 microM) and aprotinin (A, 500 tyrpsin inhibitor units [TIU]/kg) or S and soybean trypsin inhibitor (T, 500 TIU/kg), VIP caused a significantly greater decrease in PaO and greater quantities of VIP were recovered from lung effluent (both P < 0.001). The addition of captopril, (3 microM), leupeptin (4 microM), or bestatin (1 microM) failed to further increase pulmonary relaxation or recovery of VIP-LI. When given singly, A, T, and S did not augment the effects or recovery of VIP. The efficacy of S (a specific inhibitor of neutral endopeptidase [NEP]) and A and T (serine protease inhibitors) thus implicated NEP and at least one serine protease as primary modulators of VIP activity in the guinea pig lung. We sought to corroborate this finding by characterizing the predominant amino acid sites at which VIP is hydrolized in the lung. When [mono(125I)iodo-Tyr10]VIP was offered to the lung, in the presence and absence of the active inhibitors, cleavage products consistent with activity by NEP and a tryptic enzyme were recovered. These data demonstrate that NEP and a peptidase with an inhibitor profile and cleavage pattern compatible with a tryptic enzyme inactivate VIP in a physiologically competitive manner.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7678603      PMCID: PMC330019          DOI: 10.1172/JCI116176

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  38 in total

1.  Enzymatic modulation of vasoactive intestinal peptide and nonadrenergic noncholinergic inhibitory responses in guinea pig tracheae.

Authors:  D C Thompson; L Diamond; R J Altiere
Journal:  Am Rev Respir Dis       Date:  1990-11

2.  Sensory nerve depletion potentiates inhibitory non-adrenergic, non-cholinergic nerves in guinea-pig airways.

Authors:  C D Stretton; M G Belvisi; P J Barnes
Journal:  Eur J Pharmacol       Date:  1990-08-10       Impact factor: 4.432

3.  Effects of epithelium removal on relaxation of airway smooth muscle induced by vasoactive intestinal peptide and electrical field stimulation.

Authors:  S G Farmer; J Togo
Journal:  Br J Pharmacol       Date:  1990-05       Impact factor: 8.739

4.  Peptidase modulation of the pulmonary effects of tachykinins in tracheal superfused guinea pig lungs.

Authors:  M A Martins; S A Shore; N P Gerard; C Gerard; J M Drazen
Journal:  J Clin Invest       Date:  1990-01       Impact factor: 14.808

5.  Effects of phosphodiesterase inhibitors on vasoactive intestinal peptide-induced relaxation of isolated guinea-pig trachea.

Authors:  K Shikada; A Yamamoto; S Tanaka
Journal:  Eur J Pharmacol       Date:  1991-04-03       Impact factor: 4.432

6.  Distribution of vasoactive intestinal peptide- and substance P-containing nerves originating from neurons of airway ganglia in cat bronchi.

Authors:  R D Dey; J B Altemus; M Michalkiewicz
Journal:  J Comp Neurol       Date:  1991-02-08       Impact factor: 3.215

7.  Effects of [N-(L-(1-carboxy-2-phenyl)ethyl]-L-phenylalanyl-beta-alanine (SCH32615), a neutral endopeptidase (enkephalinase) inhibitor, on levels of enkephalin, encrypted enkephalins and substance P in cerebrospinal fluid and plasma of primates.

Authors:  T L Yaksh; M B Sabbe; D Lucas; E Mjanger; R E Chipkin
Journal:  J Pharmacol Exp Ther       Date:  1991-03       Impact factor: 4.030

8.  Enzymatic degradation of helodermin and vasoactive intestinal polypeptide.

Authors:  M Hachisu; T Hiranuma; S Tani; T Iizuka
Journal:  J Pharmacobiodyn       Date:  1991-03

9.  Mammalian tissue trypsin-like enzymes. Comparative reactivities of human skin tryptase, human lung tryptase, and bovine trypsin with peptide 4-nitroanilide and thioester substrates.

Authors:  T Tanaka; B J McRae; K Cho; R Cook; J E Fraki; D A Johnson; J C Powers
Journal:  J Biol Chem       Date:  1983-11-25       Impact factor: 5.157

10.  Cloning of the cDNA and gene of mouse mast cell protease-6. Transcription by progenitor mast cells and mast cells of the connective tissue subclass.

Authors:  D S Reynolds; D S Gurley; K F Austen; W E Serafin
Journal:  J Biol Chem       Date:  1991-02-25       Impact factor: 5.157

View more
  6 in total

1.  Response to oyster mushroom (Pleurotus ostreatus) extract by sensitized and nonsensitized guinea pig trachea.

Authors:  E N Schachter; E Zuskin; J Pucarin-Cvetkovic; A Chiarelli; S Goswami
Journal:  Lung       Date:  2011-06-12       Impact factor: 2.584

2.  Spatio-temporal localization of vasoactive intestinal peptide and neutral endopeptidase in allergic murine lungs.

Authors:  Amali E Samarasinghe; Scott A Hoselton; Jane M Schuh
Journal:  Regul Pept       Date:  2010-06-08

3.  Bronchodilation by an inhaled VPAC(2) receptor agonist in patients with stable asthma.

Authors:  A Lindén; L Hansson; A Andersson; M Palmqvist; P Arvidsson; C-G Löfdahl; P Larsson; J Lötvall
Journal:  Thorax       Date:  2003-03       Impact factor: 9.139

4.  Effects of chronic airway inflammation on the activity and enzymatic inactivation of neuropeptides in guinea pig lungs.

Authors:  C M Lilly; L Kobzik; A E Hall; J M Drazen
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

5.  Sorting out the cytokines of asthma.

Authors:  J M Drazen; J P Arm; K F Austen
Journal:  J Exp Med       Date:  1996-01-01       Impact factor: 14.307

6.  Mast cell tryptase and asthma.

Authors:  M Q Zhang; H Timmerman
Journal:  Mediators Inflamm       Date:  1997       Impact factor: 4.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.